Loading patent…
AssigneeImmutrix Therapeutics, Inc.
InventorsCarol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller, Jose A. Diaz-Aunon
Estimating the term…
A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.
A method of treating a subject infected with SARS-CoV-2 comprising:
An extracorporeal system for treating a subject infected with SARS-CoV-2 comprising at least three adsorbent materials, and a computer system, wherein the adsorbent materials comprise an synthetic carbon particle, a mixture of a synthetic carbon particle (SCP) and an anion exchatnre resin, wherein the weight ratio of SCP to anion exchange resin is from about 1:100, and a mixture of an synthetic carbon particle and a cation exchange resin, wherein the weight ratio of SCP to cation exchange resin is from about 1:100.
Dependencies are inferred from the claim text.